Hedy Teppler

7.4k citations

72 papers · 4.2k indexed · 1 hit paper · h-index 31

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Antifungal resistance and susceptibility

Papers in

Virology 43
- HIV Research and Treatment 43
Applied Microbiology and Biotechnology 10
- Antibiotic Use and Resistance 10

Co-authors: Bach‐Yen Nguyen Hong Wan Robert Lupinacci Carole A. Sable Johan Maertens Michael Bourque Thomas J. Walsh Lindsey R. Baden
Journals: JAIDS Journal of Acquired Immune Deficiency Syndromes (13 papers)AIDS (5 papers)Clinical Infectious Diseases (4 papers)Journal of the International AIDS Society (4 papers)Open Forum Infectious Diseases (4 papers)
Partner nations: United States France Germany

In The Last Decade

Hedy Teppler

71 papers receiving 4.1k citations

Hit Papers

align trajectories log scale

Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia 2004 · 644 citations

Peers

Countries citing papers authored by Hedy Teppler

Since Specialization

Citations

This map shows the geographic impact of Hedy Teppler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hedy Teppler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hedy Teppler more than expected).

Fields of papers citing papers by Hedy Teppler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hedy Teppler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hedy Teppler. The network helps show where Hedy Teppler may publish in the future.

Co-authors

The 25 scholars most cited alongside Hedy Teppler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hedy Teppler Line = papers co-authored together Hedy Teppler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals Contemporary Clinical Trials ·Hedy Teppler, Oliver Bautista, S.M. Elissev, Jennifer McCauley, Alain Luxembourg	2021	4
2	Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097 JAIDS Journal of Acquired Immune Deficiency Syndromes ·Diana F. Clarke, Rodolfo Garcia Z., Edward P. Acosta, Linda Harms-Smith, Jiajia Wang, Stephen A. Spector, Anne Chain, Elizabeth Smith, Hedy Teppler, Rohan Hazra, Xiao-Qing Nie, Bobbie Graham, Stella KARRA, Yvonne J. Bryson, Mark Mirochnick	2020	1
3	Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study AIDS Research and Human Retroviruses ·Sonja Paramita Schrader, Cecilia L. Moore, Eduardo Gotuzzo, 张怀栓, Adeeba Kamarulzaman, Ploenchan Chetchotisakd, Jean van Wyk, Hedy Teppler, Nagalingeswaran Kumarasamy, Jean‐Michel Molina, Sean Emery, David A. Cooper, Mark Boyd, (unknown)	2016	12
4	Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV‐infected children 4 weeks to 18 years of age The Journal of Clinical Pharmacology ·Matthew L. Rizk, Lihong Du, Salsa Putri, Larissa Wenning, Hedy Teppler, Савицкий Василий Васильевич, Bobbie Graham, A K Pedersen, Sharon Nachman, Andrew Wiznia, Carol Worrell, Betsy Smith, Edward P. Acosta	2015	13
5	Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection PLoS ONE ·Janaki Amin, Mark Boyd, Nagalingeswaran Kumarasamy, Cecilia L. Moore, M Losso, 张怀栓, Lerato Mohapi, Stephen J. Kerr, Annette H. Sohn, Hedy Teppler, Boris Renjifo, Jean‐Michel Molina, Sean Emery, David A. Cooper	2015	31
6	Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age Journal of the Pediatric Infectious Diseases Society ·Sharon Nachman, Rachel Lynn Hoag, Edward P. Acosta, Hedy Teppler, Савицкий Василий Васильевич, Bobbie Graham, T. Fenton, Xia Xu, Matthew L. Rizk, Stephen A. Spector, Lisa M. Frenkel, Annik. Auteur du texte Le Guen, Edward Handelsman, Andrew Wiznia	2015	24
7	Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis The Lancet HIV ·Mark Boyd, Cecilia L. Moore, Jean‐Michel Molina, Robin Wood, Juan Sierra Madero, Marcelo Wolff, Kiat Ruxrungtham, Marcelo Losso, Boris Renjifo, Hedy Teppler, Anthony D. Kelleher, Janaki Amin, Sean Emery, David A. Cooper	2015	63
8	Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing JAIDS Journal of Acquired Immune Deficiency Syndromes ·Diana F. Clarke, Edward P. Acosta, Matthew L. Rizk, Yvonne J. Bryson, Stephen A. Spector, Lynne Mofenson, Edward Handelsman, Hedy Teppler, Faizal Abda Ashari, Deborah Persaud, Linda Harms-Smith, Viviane de Campos, Mark Mirochnick	2014	35
9	Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients Journal of the International AIDS Society ·Josep M. Gatell, نانسي ساكي, Debbie Hagins, Melanie Thompson, Keikawus Arastéh, Christian Hoffmann, Sorin Rugină, Olayemi Osiyemi, Gurung Rit Bahadur, Robin Dretler, Marcelo Alejo Calle, Xia Xu, Hedy Teppler	2014	45
10	Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK HIV Clinical Trials ·Edwin DeJesus, Jürgen K. Rockstroh, Jeffrey L. Lennox, Michael S. Saag, Adriano Lazzarin, Jing Zhao, Hong Wan, Anthony Rodgers, Ayomide D. Ayodele, Michael D. Miller, Mark J. DiNubile, Bach‐Yen Nguyen, Hedy Teppler, Randi Y. Leavitt, Peter Sklar, (unknown)	2012	26
11	Long-Term Safety from the Raltegravir Clinical Development Program Current HIV Research ·Hedy Teppler, Deborah D. Brown, Randi Y. Leavitt, Peter Sklar, Hong Wan, Xia Xu, Fabio Lievano, XV Ciclo, T. Christopher Mast, Bach‐Yen Nguyen	2011	30
12	Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK Clinical Infectious Diseases ·Jürgen K. Rockstroh, Jeffrey L. Lennox, Edwin DeJesus, Michael S. Saag, Adriano Lazzarin, Hong Wan, Ayomide D. Ayodele, Xia Xu, Jing Zhao, Hedy Teppler, Mark J. DiNubile, Anthony Rodgers, Bach-Yen Nguyen, Randi Y. Leavitt, Peter Sklar	2011	139
13	Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies AIDS ·Jürgen K. Rockstroh, Hedy Teppler, Jing Zhao, Peter Sklar, Michael D. Miller, Charlotte M. Harvey, Kim M. Strohmaier, Randi Y. Leavitt, Bach‐Yen Nguyen	2011	23
14	Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger, Adriano Lazzarin, Richard B. Pollard, José Valdez Madruga, Jing Zhao, Hong Wan, Christopher L. Gilbert, Hedy Teppler, Anthony Rodgers, Richard J. O. Barnard, Michael D. Miller, Mark J. DiNubile, Bach-Yen Nguyen, Randi Y. Leavitt, Peter Sklar	2010	194
15	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase AIDS ·John M. Murray, Sean Emery, Anthony D. Kelleher, Matthew Law, Joshua Chen, Daria J. Hazuda, Bach‐Yen Nguyen, Hedy Teppler, David A. Cooper	2007	151
16	Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study Transplant Infectious Disease ·B.E. de Pauw, Carole A. Sable, Thomas J. Walsh, Robert Lupinacci, Michael Bourque, examiner Yuni Krisyuningsih Krisnandi, Д.М. Зиннатова, Mark J. DiNubile, Hedy Teppler	2006	28
17	Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248) JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mary Vogler, Hedy Teppler, Rebecca Gelman, Fred Valentine, Michael M. Lederman, Roger J. Pomerantz, Richard B. Pollard, shiho Yamashita, Charles J. Gonzalez, Kathleen Squires, Ian Frank, Donna Mildvan, Kazlauskas, Tadas,, Barbara Schock	2004	15
18	Surgical Infections with Enterococcus : Outcome in Patients Treated with Ertapenem versus Piperacillin-Tazobactam Surgical Infections ·Hedy Teppler, Kathleen McCarroll, Richard Gesser, Gail L. Woods	2002	33
19	Ertapenem versus Piperacillin-Tazobactam for Treatment of Mixed Anaerobic Complicated Intra-Abdominal, Complicated Skin and Skin Structure, and Acute Pelvic Infections Surgical Infections ·José M. Tellado, Gail L. Woods, Richard Gesser, Kathleen McCarroll, Hedy Teppler	2002	17
20	Ertapenem Once a Day Versus Piperacillin–Tazobactam Every6 Hours for Treatment of Acute Pelvic Infections:A Prospective, Multicenter, Randomized, Double‐Blind Study Infectious Diseases in Obstetrics and Gynecology ·Subir Roy, F. L�tgemeier, Edith Ángel‐Müller, Mahmoud Ismail, Shelley L. Neilsen, Ben Adeyi, Gail L. Woods, Hedy Teppler	2002	49

About Hedy Teppler

Hedy Teppler is a scholar working on Virology, Applied Microbiology and Biotechnology, Infectious Diseases, Molecular Medicine and Emergency Medicine, having authored 72 papers that have together received 4.2k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (43 papers), HIV/AIDS Research and Interventions (18 papers), Antibiotic Use and Resistance (10 papers), Pharmacological Effects and Toxicity Studies (9 papers), Antibiotics Pharmacokinetics and Efficacy (9 papers), HIV-related health complications and treatments (9 papers) and Antibiotic Resistance in Bacteria (6 papers). The work is most often cited by research in Virology (1.9k citations), Infectious Diseases (3.2k citations), Applied Microbiology and Biotechnology (252 citations), Emergency Medicine (599 citations) and Molecular Medicine (267 citations). Hedy Teppler has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Bach‐Yen Nguyen, Hong Wan, Robert Lupinacci, Carole A. Sable, Johan Maertens, Michael Bourque, Thomas J. Walsh, Lindsey R. Baden, Oliver A. Cornely and Gerald R. Donowitz. Their work appears in journals such as JAIDS Journal of Acquired Immune Deficiency Syndromes, AIDS, Clinical Infectious Diseases, Journal of the International AIDS Society and Open Forum Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact